ATON is a medical science group committed to the future of medicine, with the aim of improving patient care and the safety and efficacy of treatments. ATON guides and develops a portfolio of cutting-edge companies, each with its own specialty, working in synergy to advance the medicine of today and tomorrow.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

04-30	Aton Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	Aton Auditor Raises 'Going Concern' Doubt	CI

Market Cap	9.77M 11.21M 9.2M 8.38M 15.71M 1.07B 15.73M 110M 42.48M 547M 42.1M 41.17M 1.76B	P/E 2024	-4.95x	P/E 2025	-6.08x
Enterprise Value	14.27M 16.37M 13.44M 12.24M 22.95M 1.57B 22.98M 161M 62.03M 799M 61.47M 60.11M 2.58B	EV / Sales 2024	20.3x	EV / Sales 2025	15.8x
Free-Float	87.28%	Yield 2024 *	-	Yield 2025	-

04-30	Aton Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-29	Aton Auditor Raises 'Going Concern' Doubt	CI
03-20	ATON Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-18	Aton Group Appoints Hadrien Lanvin as Deputy CEO	CI
25-10-30	Aton Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-03	Portage Biotech Inc. will Change its Ticker to ATON from PRTG	CI
25-04-28	Aton Auditor Raises 'Going Concern' Doubt	CI
24-07-04	Aton Reports the Results from Its Phase 2 Diamond Drilling Programme At the Semna Gold Mine, Including 11.69 G/T Au and 1.38% Cu over an Interval of 5.19 Metres	CI
24-06-25	Glassbox Launches Global Partner Network to Drive Enterprise Digital Transformation with AI-Powered CX Solutions	CI
24-06-04	ITALY GROWTH WINNERS & LOSERS: Bullish plants; Aton Green at the back of the pack.	AN
24-05-07	ATON board of directors chooses Uguzzoni as CEO and appoints Nervosi as vice chairman	AN
24-03-22	ATON Green Storage, profit halved in 2023 and revenues drop	AN
24-03-22	Aton Resources Issues Shares To Settle $6.3 Million Debt	MT

03-23	ATON : PARTICIPE AU EUROPEAN MIDCAP EVENT 2025 À PARIS DU 30 SEPTEMBRE AU 1ER OCTOBRE	PU
03-11	Aton : ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC	AT
02-18	ATON : APPOINTS HADRIEN LANVIN AS DEPUTY CEO	PU
02-18	Aton : ATON APPOINTS HADRIEN LANVIN AS DEPUTY CEO	AT
25-10-10	ATON : Partnership bewteen Inoviem Scientific and Abc Biopply AG	PU

08-24	ATON : Tableau suivi des BEORA (ATON Tableau de suivi des BEORA 4)
08-24	ATON : Tableau de suivi des BEORA (ATON Tableau de suivi des BEORA)
08-24	Aton : ATON ANNONCE LE REMBOURSEMENT INTEGRAL DES ORA SOUSCRITES AUPRES D’IRIS CAPITAL
08-10	ATON : Untitled (Hybrigenics Calcul du detention au 100826)
08-07	ATON : Tableau suivi des BEORA (Hybrigenics Calcul du detention au 070826 1)

Hybrigenics SA Stock Xetra

Stocks

3HB

FR0004153930

Advanced Medical Equipment & Technology

Valuation: Hybrigenics SA

Latest news: Hybrigenics SA

Analysts' recommendations: Hybrigenics SA

Press Releases: Hybrigenics SA

News in other languages: Hybrigenics SA

Managers and Directors: Hybrigenics SA

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Manager	Title	Age	Since
Ayikoélé Léone Atayi CEO	Chief Executive Officer	-	2022-01-05
Hadrien Lanvin PRN	Corporate Officer/Principal	-	2026-02-17

Director	Title	Age	Since
Ayikoélé Léone Atayi CHM	Chairman	-	2023-12-19
Pierre Eftekhari BRD	Director/Board Member	-	2021-09-20
Virginie Miath BRD	Director/Board Member	-	2023-12-19

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERMO FISHER SCIENTIFIC, INC.	+1.12%	+7.36%	+37.36%	+31.33%	244B
DANAHER CORPORATION	+1.90%	+6.19%	+11.67%	-13.54%	152B
INTUITIVE SURGICAL, INC.	+2.12%	+6.27%	-8.45%	+41.25%	142B
BOSTON SCIENTIFIC CORPORATION	+0.88%	-2.95%	-55.31%	-18.99%	63.36B
EDWARDS LIFESCIENCES CORPORATION	+0.09%	+3.30%	+18.72%	+25.88%	50.92B
SIEMENS HEALTHINEERS AG	-0.75%	-2.60%	-19.29%	-20.24%	48.47B
AGILENT TECHNOLOGIES, INC.	+3.50%	+10.31%	+28.20%	+47.58%	45.66B
WATERS CORPORATION	+0.54%	+3.39%	+40.90%	+57.67%	41.65B
ILLUMINA, INC.	-0.33%	+14.70%	+132.43%	+79.12%	36.06B
Average	+0.43%	+4.83%	+20.69%	+25.56%	91.48B
Weighted average by Cap.	+0.11%	+5.46%	+16.95%	+21.85%

	2024	2025
Net sales	614K 704K 578K 527K 987K 67.47M 989K 6.93M 2.67M 34.37M 2.65M 2.59M 111M	661K 758K 623K 567K 1.06M 72.63M 1.06M 7.46M 2.87M 37M 2.85M 2.78M 119M
Net income	-1.1M -1.26M -1.04M -944K -1.77M -121M -1.77M -12.42M -4.79M -61.63M -4.74M -4.64M -199M	-962K -1.1M -906K -825K -1.55M -106M -1.55M -10.85M -4.18M -53.84M -4.14M -4.05M -174M
Net Debt	4.57M 5.24M 4.3M 3.92M 7.35M 502M 7.36M 51.54M 19.86M 256M 19.68M 19.25M 825M	4.5M 5.16M 4.24M 3.86M 7.23M 494M 7.24M 50.72M 19.55M 252M 19.37M 18.94M 812M

End-of-day quote Xetra
- ^EUR	-